Efficacy and safety of pazopanib, everolimus and nivolumab in patients with metastatic renal cell carcinoma: a real life study

Trial Profile

Efficacy and safety of pazopanib, everolimus and nivolumab in patients with metastatic renal cell carcinoma: a real life study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Everolimus (Primary) ; Nivolumab (Primary) ; Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PAZOREAL
  • Most Recent Events

    • 12 Sep 2017 Interim results (n=305) presented at the 42nd European Society for Medical Oncology Congress.
    • 03 Dec 2016 New trial record
    • 11 Oct 2016 Four interim analyses are planned, and the first analysis will be performed in April 2017 as per trial design presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top